Key points for investors:
- Strong commercial performance: Q1 total revenue $191.2M, up 57% YoY, driven by AUVELITY ($153.2M, +59% YoY), SUNOSI ($33.9M, +34% YoY) and SYMBRAVO ($4.1M). AUVELITY wrote ~223k scripts in the quarter (35% YoY growth).
- Major regulatory milestone: FDA approved AUVELITY for agitation associated with Alzheimer's disease (breakthrough designation / priority review). This expands AUVELITY to two breakthrough-designation indications (MDD and Alzheimer's agitation).
- Updated peak sales outlook: Management now estimates AUVELITY potential of at least $8 billion annual peak revenue, with roughly equal contribution from MDD and Alzheimer's agitation.
- Commercial buildout: AUVELITY sales force expanded to ~630 reps covering ~68,000 HCP targets (primary care, psychiatry, neurology, geriatrics); SYMBRAVO sales team expanded to ~150 reps and secured payer coverage for ~17M lives; SUNOSI maintains ~83% coverage.
- Pipeline progress: NDA submitted for AXS-12 (cataplexy in narcolepsy); plan to start multiple Phase III trials in coming months; ENGAGE Phase III (solriamfetol in binge-eating disorder) top-line expected H2 2026; CLARITY randomized-withdrawal Phase III (solriamfetol in MDD w/ excessive daytime sleepiness) initiated; AXS-14 Phase III (fibromyalgia) enrolling; acquired AXS-20 (balipodect, PDE10A inhibitor) with Phase III-enabling work and planned schizophrenia program.
- Financials and operating cadence: Higher R&D ($52.7M) and SG&A ($185M) reflecting one-time acquisition expenses and accelerated prelaunch/commercial activities. Q1 net loss $64.5M ($1.26/share) including $23.4M stock-comp. Cash & equivalents $305M (down from $323M year-end) and management states cash runway into cash flow positivity under current plan.
- Gross-to-net dynamics: AUVELITY and SUNOSI gross-to-net discounts low-to-mid-50s in Q1 with expected improvement; SYMBRAVO G/N high-70s near-term but expected to evolve as access builds.
- Strategy & risk: Focused on a "singular CNS" portfolio — commercialize three differentiated marketed products across four indications and advance a deep late-stage pipeline. Company cautioned that forward-looking statements are subject to usual clinical, regulatory, market and execution risks.
Overall investor takeaway: Axsome is transitioning from rapid commercial scale-up into a phase where a recently expanded sales force, a new label for AUVELITY in Alzheimer's agitation, improved payer access, and multiple near-term clinical catalysts position the company for substantial revenue growth, while near-term profitability is still a function of continued top-line growth versus elevated SG&A and R&D investment.
Sign In
Buy AXSM
